Is JANX or RLAY more profitable?

Janux Therapeutics' return on equity of -11.89% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Janux Therapeutics N/A -11.89% -11.13% Relay Therapeutics N/A -42.27% -38.67%

Does the media refer more to JANX or RLAY?

In the previous week, Janux Therapeutics and Janux Therapeutics both had 3 articles in the media. Relay Therapeutics' average media sentiment score of 0.65 beat Janux Therapeutics' score of -0.44 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Relay Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CELC or JANX more profitable?

Janux Therapeutics' return on equity of -11.89% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -350.78% -41.54% Janux Therapeutics N/A -11.89% -11.13%

Does the media favor CELC or JANX?

In the previous week, Celcuity had 3 more articles in the media than Janux Therapeutics. MarketBeat recorded 6 mentions for Celcuity and 3 mentions for Janux Therapeutics. Celcuity's average media sentiment score of 0.43 beat Janux Therapeutics' score of -0.44 indicating that Celcuity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Janux Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is JANX or TNGX more profitable?

Janux Therapeutics' return on equity of -11.89% beat Tango Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Janux Therapeutics N/A -11.89% -11.13% Tango Therapeutics N/A -25.75% -23.36%

Does the media refer more to JANX or TNGX?

In the previous week, Tango Therapeutics had 3 more articles in the media than Janux Therapeutics. MarketBeat recorded 6 mentions for Tango Therapeutics and 3 mentions for Janux Therapeutics. Tango Therapeutics' average media sentiment score of 0.89 beat Janux Therapeutics' score of -0.44 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Tango Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is JANX or ELVN more profitable?

Janux Therapeutics' return on equity of -11.89% beat Enliven Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Janux Therapeutics N/A -11.89% -11.13% Enliven Therapeutics N/A -18.55% -18.09%

Does the media favor JANX or ELVN?

In the previous week, Enliven Therapeutics had 4 more articles in the media than Janux Therapeutics. MarketBeat recorded 7 mentions for Enliven Therapeutics and 3 mentions for Janux Therapeutics. Enliven Therapeutics' average media sentiment score of 0.56 beat Janux Therapeutics' score of -0.44 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Enliven Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor JANX or IOVA?

In the previous week, Iovance Biotherapeutics had 11 more articles in the media than Janux Therapeutics. MarketBeat recorded 14 mentions for Iovance Biotherapeutics and 3 mentions for Janux Therapeutics. Iovance Biotherapeutics' average media sentiment score of 0.68 beat Janux Therapeutics' score of -0.44 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Iovance Biotherapeutics 5 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Janux Therapeutics (JANX) Competitors

$16.52 -0.95 (-5.44%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$16.26 -0.26 (-1.60%)

As of 09/23/2026 07:33 PM Eastern

Compare

JANX vs. RLAY, CELC, TNGX, ELVN, and IOVA

Should you buy Janux Therapeutics stock or one of its competitors? Janux Therapeutics's main competitors and comparable companies include Relay Therapeutics (RLAY), Celcuity (CELC), Tango Therapeutics (TNGX), Enliven Therapeutics (ELVN), and Iovance Biotherapeutics (IOVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Janux Therapeutics compare to Relay Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

In the previous week, Janux Therapeutics and Janux Therapeutics both had 3 articles in the media. Relay Therapeutics' average media sentiment score of 0.65 beat Janux Therapeutics' score of -0.44 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Relay Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Janux Therapeutics has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	101.00	-$113.62M	-$1.64	N/A
Relay Therapeutics	$10.35M	381.75	-$276.48M	-$1.57	N/A

Janux Therapeutics has a beta of 2.53, indicating that its share price is 153% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market.

Janux Therapeutics currently has a consensus price target of $36.46, suggesting a potential upside of 120.71%. Relay Therapeutics has a consensus price target of $25.92, suggesting a potential upside of 43.74%. Given Janux Therapeutics' higher probable upside, equities research analysts plainly believe Janux Therapeutics is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Janux Therapeutics' return on equity of -11.89% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Relay Therapeutics	N/A	-42.27%	-38.67%

Summary

Janux Therapeutics and Relay Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Janux Therapeutics compare to Celcuity?

Celcuity (NASDAQ:CELC) and Janux Therapeutics (NASDAQ:JANX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Celcuity has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.53, meaning that its share price is 153% more volatile than the broader market.

63.3% of Celcuity shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 13.3% of Celcuity shares are held by insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Janux Therapeutics' return on equity of -11.89% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
Janux Therapeutics	N/A	-11.89%	-11.13%

Celcuity presently has a consensus price target of $154.75, indicating a potential upside of 93.46%. Janux Therapeutics has a consensus price target of $36.46, indicating a potential upside of 120.71%. Given Janux Therapeutics' higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Celcuity had 3 more articles in the media than Janux Therapeutics. MarketBeat recorded 6 mentions for Celcuity and 3 mentions for Janux Therapeutics. Celcuity's average media sentiment score of 0.43 beat Janux Therapeutics' score of -0.44 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Janux Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Janux Therapeutics has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Janux Therapeutics	$10M	101.00	-$113.62M	-$1.64	N/A

Summary

Janux Therapeutics beats Celcuity on 10 of the 15 factors compared between the two stocks.

How does Janux Therapeutics compare to Tango Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

In the previous week, Tango Therapeutics had 3 more articles in the media than Janux Therapeutics. MarketBeat recorded 6 mentions for Tango Therapeutics and 3 mentions for Janux Therapeutics. Tango Therapeutics' average media sentiment score of 0.89 beat Janux Therapeutics' score of -0.44 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Tango Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Tango Therapeutics has higher revenue and earnings than Janux Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	101.00	-$113.62M	-$1.64	N/A
Tango Therapeutics	$62.38M	66.09	-$101.59M	-$0.85	N/A

Janux Therapeutics has a beta of 2.53, indicating that its share price is 153% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Janux Therapeutics' return on equity of -11.89% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Tango Therapeutics	N/A	-25.75%	-23.36%

Janux Therapeutics presently has a consensus target price of $36.46, indicating a potential upside of 120.71%. Tango Therapeutics has a consensus target price of $43.46, indicating a potential upside of 77.76%. Given Janux Therapeutics' higher probable upside, analysts clearly believe Janux Therapeutics is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Janux Therapeutics and Tango Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Janux Therapeutics compare to Enliven Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Janux Therapeutics currently has a consensus target price of $36.46, suggesting a potential upside of 120.71%. Enliven Therapeutics has a consensus target price of $75.00, suggesting a potential upside of 62.73%. Given Janux Therapeutics' higher probable upside, research analysts plainly believe Janux Therapeutics is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Janux Therapeutics' return on equity of -11.89% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Enliven Therapeutics	N/A	-18.55%	-18.09%

In the previous week, Enliven Therapeutics had 4 more articles in the media than Janux Therapeutics. MarketBeat recorded 7 mentions for Enliven Therapeutics and 3 mentions for Janux Therapeutics. Enliven Therapeutics' average media sentiment score of 0.56 beat Janux Therapeutics' score of -0.44 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Enliven Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enliven Therapeutics has lower revenue, but higher earnings than Janux Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	101.00	-$113.62M	-$1.64	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Janux Therapeutics has a beta of 2.53, suggesting that its share price is 153% more volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

Summary

Janux Therapeutics beats Enliven Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Janux Therapeutics compare to Iovance Biotherapeutics?

Janux Therapeutics (NASDAQ:JANX) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Janux Therapeutics has higher earnings, but lower revenue than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	101.00	-$113.62M	-$1.64	N/A
Iovance Biotherapeutics	$263.50M	17.52	-$390.98M	-$0.73	N/A

Janux Therapeutics has a beta of 2.53, indicating that its stock price is 153% more volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Janux Therapeutics currently has a consensus target price of $36.46, indicating a potential upside of 120.71%. Iovance Biotherapeutics has a consensus target price of $9.11, indicating a potential downside of 10.59%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Janux Therapeutics is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45

In the previous week, Iovance Biotherapeutics had 11 more articles in the media than Janux Therapeutics. MarketBeat recorded 14 mentions for Iovance Biotherapeutics and 3 mentions for Janux Therapeutics. Iovance Biotherapeutics' average media sentiment score of 0.68 beat Janux Therapeutics' score of -0.44 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Iovance Biotherapeutics	5 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Janux Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -89.11%. Janux Therapeutics' return on equity of -11.89% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%

Summary

Janux Therapeutics beats Iovance Biotherapeutics on 12 of the 17 factors compared between the two stocks.

Get Janux Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JANX vs. The Competition

Export

Metric	Janux Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.07B	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-10.07	13.88	274.02	25.69
Price / Sales	101.00	1,311.41	633.28	76.04
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	1.04	15.30	10.44	6.32
Net Income	-$113.62M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-2.02%	-1.71%	-0.66%	0.17%
1 Month Performance	-11.18%	-6.17%	-3.16%	-3.27%
1 Year Performance	-27.67%	30.64%	15.15%	5.58%

Janux Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JANX Janux Therapeutics	2.605 of 5 stars	$16.52 -5.4%	$36.46 +120.7%	-28.1%	$1.07B	$10M	N/A	113
RLAY Relay Therapeutics	2.3771 of 5 stars	$19.06 +1.0%	$25.92 +36.0%	+305.2%	$4.14B	$10.35M	N/A	192
CELC Celcuity	2.7305 of 5 stars	$83.53 +0.1%	$154.55 +85.0%	+52.4%	$4.08B	N/A	N/A	155	Positive News High Trading Volume
TNGX Tango Therapeutics	2.8296 of 5 stars	$24.54 +3.2%	$43.46 +77.1%	+235.9%	$4.01B	$62.38M	N/A	137
ELVN Enliven Therapeutics	2.286 of 5 stars	$54.43 +0.2%	$75.00 +37.8%	+140.2%	$3.98B	N/A	N/A	67	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JANX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Janux Therapeutics (JANX) Competitors

JANX vs. RLAY, CELC, TNGX, ELVN, and IOVA

How does Janux Therapeutics compare to Relay Therapeutics?

Summary

How does Janux Therapeutics compare to Celcuity?

Summary

How does Janux Therapeutics compare to Tango Therapeutics?

Summary

How does Janux Therapeutics compare to Enliven Therapeutics?

Summary

How does Janux Therapeutics compare to Iovance Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX vs. The Competition

Janux Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Janux Therapeutics (JANX) Competitors

JANX vs. RLAY, CELC, TNGX, ELVN, and IOVA

How does Janux Therapeutics compare to Relay Therapeutics?

Does the media refer more to JANX or RLAY?

Do institutionals and insiders hold more shares of JANX or RLAY?

Which has stronger valuation and earnings, JANX or RLAY?

Which has more volatility and risk, JANX or RLAY?

Do analysts prefer JANX or RLAY?

Is JANX or RLAY more profitable?

Summary

How does Janux Therapeutics compare to Celcuity?

Which has more risk and volatility, CELC or JANX?

Do insiders & institutionals believe in CELC or JANX?

Is CELC or JANX more profitable?

Do analysts rate CELC or JANX?

Does the media favor CELC or JANX?

Which has preferable earnings and valuation, CELC or JANX?

Summary

How does Janux Therapeutics compare to Tango Therapeutics?

Does the media refer more to JANX or TNGX?

Do insiders & institutionals believe in JANX or TNGX?

Which has better valuation and earnings, JANX or TNGX?

Which has more volatility & risk, JANX or TNGX?

Is JANX or TNGX more profitable?

Do analysts rate JANX or TNGX?

Summary

How does Janux Therapeutics compare to Enliven Therapeutics?

Do analysts recommend JANX or ELVN?

Is JANX or ELVN more profitable?

Does the media favor JANX or ELVN?

Which has better earnings and valuation, JANX or ELVN?

Do institutionals & insiders have more ownership in JANX or ELVN?

Which has more volatility and risk, JANX or ELVN?

Summary

How does Janux Therapeutics compare to Iovance Biotherapeutics?

Which has stronger earnings and valuation, JANX or IOVA?

Which has more risk and volatility, JANX or IOVA?

Do insiders & institutionals hold more shares of JANX or IOVA?

Do analysts rate JANX or IOVA?

Does the media favor JANX or IOVA?

Is JANX or IOVA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX vs. The Competition

Janux Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools